Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-09-30

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multiple Sclerosis (MS) is the most common neurological disorder causing disability in young adults affecting approximately 1 in 1.000 people in western countries. The clinical manifestations usually begin at the age of 20 to 40 years with a median age of 28 years at onset with acute episodes of neurological dysfunction, followed by periods of partial or complete remission and clinical stability in between relapses. This relapsing-remitting phase (RR-MS) of the disease is usually followed by progressive clinical disability (secondary progressive phase, SP-MS).

At present, there is no cure for MS. Based on the pathological concept that neuroinflammation is the common element leading or contributing to neurodegenerative changes, immune interventions have been introduced into clinical practice such as Natalizumab (Tysabri), a humanized monoclonal antibody. Natalizumab (Tysabri) is indicated as a disease-modifying monotherapy of highly active relapsing MS. The associated risks, especially progressive multifocal leukoencephalopathy, necessitate active monitoring of patients and a continuous discussion of optimum use of this drug. In clinical practice, the question how to manage patients on natalizumab at a higher risk for progressive multifocal leukoencephalopathy remains unresolved.

This prospective, controlled (comparison to the period prior to natalizumab treatment), single-arm, open-label, multi-centre, phase IV study aims to evaluating the concept of natalizumab de-escalation to interferon-beta-1b e.o.d in relapsing-remitting multiple sclerosis patients, who consider stopping natalizumab due to a benefit-risk assessment. In particular, to evaluating if interferon beta-1b treatment may be able to overcome the recurrence of significant clinical and radiological disease activity after natalizumab cessation and may keep disease activity better under control as compared to the time prior to natalizumab.

The study population includes patients with relapsing-remitting multiple sclerosis (RR-MS) being treated at least for 12 months with natalizumab and having decided to stop natalizumab treatment and to de-escalate their therapy to a first line treatment with interferon beta-1b. They will be treated during 12 months with interferon-beta 1b 250 mcg given subcutaneously every other day. A 12-month follow-up period with the same treatment is planned.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Natalizumab De-escalation With Interferon Beta-1b

NCT01144052

Relapsing-remitting Multiple Sclerosis

COMPLETED PHASE4

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

NCT02241785

Relapsing Multiple Sclerosis

TERMINATED PHASE4

Treatment Interruption of Natalizumab

NCT01071083

Relapsing Remitting Multiple Sclerosis

COMPLETED PHASE2

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

NCT00134563

Multiple Sclerosis

COMPLETED PHASE3

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

NCT00027300

Multiple Sclerosis, Relapsing-Remitting

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsing-remitting Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interferon beta-1b

Interferon beta-1b 250 mcg s.c. every other day

Group Type EXPERIMENTAL

Interferon beta-1b

Intervention Type DRUG

250 mcg, s.c., each other day for 12 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Interferon beta-1b

250 mcg, s.c., each other day for 12 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Betaferon®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female or male patients with relapsing-remitting forms of multiple sclerosis (according to McDonald's criteria);
* Age between 18 and 70 years;
* Natalizumab-treatment for at least 12 months following the current Swiss guidelines for treatment initiation;
* Treated with a disease-modifying therapy other than interferon beta-1b for at least 12 months before natalizumab was initiated;
* Never treated with interferon beta-1b;
* Eligible patients are clinically stable (free from relapses and 6-month confirmed disability progression for at least 6 months) while on natalizumab-treatment and do not show any Gd-enhancement on their last MRI performed while on Tysabri;
* In eligible patients MRI were performed in the past as following

* 6-18 months prior to natalizumab-treatment
* at natalizumab start
* 12 months after natalizumab initiation;
* Good records with regard to clinical disease activity (relapse rate, EDSS progression) in the year prior to natalizumab and during natalizumab;
* Patients who decide to stop natalizumab treatment after a careful benefit/risk assessment. Risk for PML increases with duration of natalizumab exposure, pre-treatment with an immunosuppressant agent or serological status of anti-JC-virus positivity;
* Patients, who in context with cessation of natalizumab have decided, after a careful benefit/risk assessment, to continue treatment of their MS with Interferon beta-1b;
* Women of potential childbearing with active contraceptive methods;
* Patients who are willing to undergo study procedures;
* Patients who are willing to undergo MRI;
* Patients who are willing and able to sign informed consent.

Exclusion Criteria

* Patients who have previously entered this study;
* Natalizumab-treatment for less than 12 months following the current Swiss guidelines for treatment initiation;
* Prior treatment with interferon beta-1b (ever interferon beta-1b);
* Sign of clinical disease activity within the 6 months;
* One or more relapses and/or 6-month confirmed disability progression during the 6 months prior to the study;
* Secondary progressive MS;
* Primary progressive MS;
* Pregnancy - Serum pregnancy test at screening visit positive- or breast feeding;
* Uncontrolled, clinically significant heart diseases, such as arrhythmias, angina, or uncompensated congestive heart failure;
* History of severe depression or attempted suicide or current suicidal ideation;
* Medical or psychiatric conditions that compromise the ability to give informed consent, to comply with the protocol, or to complete the study;
* Uncontrolled seizure disorder;
* Myopathy or clinically significant liver disease;
* Inability, in the opinion of the principal investigator or staff, to comply with protocol requirements for the duration of the study;
* Known hypersensitivity to interferon-beta or other human proteins including albumin;
* Any contraindication for MRI or contrast administration;
* A history of drug abuse in the 6 months prior to screening;
* Treatment with any of the following in the 30 days before day 1: systemic corticosteroids, ACTH, or other investigational drugs;
* Participation in any other study involving investigational or marketed products, concomitantly or within 30 days prior to entry in the study;
* Current participation on other clinical trials;
* Treatment with drugs which might interfere with the evaluation of study drugs during the study protocol such as immunomodulants, immunosuppressives other than interferon beta-1b;
* Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol such as immunomodulants, immunosuppressives other than interferon beta-1b.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No